ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,192Medicare Part D Prescriptions Filled, Including Refills

Rank: 634 out of 5176

$779K Total Retail Price of All Prescriptions

Rank: 488 out of 5176

477 Patients Receiving at Least One Drug in Part D
84%Patients 65 Years and Older
67% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New York
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

1% of this provider’s 8,776 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

30% of this provider’s prescriptions were for brand-name drugs, compared to an average of 30%.

Prescription Price

$76 was the average price of a prescription from this provider, compared to $69 among peers.

Prescriptions per Patient

21 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New York
SIMVASTATIN 851 756 1 1
LISINOPRIL 361 296 2 5
LOSARTAN POTASSIUM 311 267 3 14
METFORMIN HCL 285 214 4 7
OMEPRAZOLE 275 229 5 3
METOPROLOL SUCCINATE 272 259 6 11
LEVOTHYROXINE SODIUM 271 238 7 4
MELOXICAM 248 217 8 53
AMLODIPINE BESYLATE 206 195 9 2
FAMOTIDINE 187 158 10 58
GABAPENTIN 167 141 11 21
CARVEDILOL 162 143 12 24
LOVAZA 155 107 13 43
CRESTOR 154 111 14 15
PRAVASTATIN SODIUM 146 135 15 23
TAMSULOSIN HCL 142 141 16 20
CALCITONIN-SALMON 140 140 17 293
JANUVIA 125 105 18 25
ZOLPIDEM TARTRATE 125 118 18 17
ATENOLOL 122 118 20 12
NEXIUM 102 71 21 16
CHLORTHALIDONE 102 100 21 122
METOPROLOL TARTRATE 100 83 23 6
CLOPIDOGREL 100 78 23 26
ACTOS 100 78 23 85
ATORVASTATIN CALCIUM 99 80 26 9
PLAVIX 99 85 26 29
ENALAPRIL MALEATE 97 77 28 22
HYDROCHLOROTHIAZIDE 86 69 29 10
LISINOPRIL-HYDROCHLOROTHIAZIDE 85 72 30 49
WARFARIN SODIUM 83 83 31 13
FUROSEMIDE 83 78 31 8
DIOVAN 83 78 31 19
FINASTERIDE 76 76 34 69
ALENDRONATE SODIUM 73 67 35 18
ADVAIR DISKUS 72 63 36 32
DIOVAN HCT 72 67 36 39
PRADAXA 71 71 38 192
METFORMIN HCL ER 71 64 38 57
CLOTRIMAZOLE-BETAMETHASONE 68 44 40 94
WELCHOL 60 59 41 230
AMLODIPINE BESYLATE-BENAZEPRIL 59 49 42 55
GLIMEPIRIDE 58 51 43 37
ALLOPURINOL 55 51 44 41
DONEPEZIL HCL 54 50 45 28
AMITRIPTYLINE HCL 54 49 R 45 177
ATENOLOL-CHLORTHALIDONE 54 52 45 161
FLUTICASONE PROPIONATE 53 38 48 38
JANUMET 52 39 49 77
DIGOXIN 52 46 49 56
AMMONIUM LACTATE 52 43 49 91
SERTRALINE HCL 52 37 49 30
AGGRENOX 51 42 53 235
VENTOLIN HFA 50 39 54 64
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Dec. 20, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.